Mycovia Pharmaceuticals

South Korea’s SK Bioscience voluntarily withdrew its EU conditional marketing authorization application (MAA) for SKYCovion/GBP510, a recombinant COVID-19 vaccine, on 1 September, ahead of this week’s

The European Medicines Agency has begun evaluating EU marketing authorization applications (MAAs) for a new batch of investigational drugs, of which two – polyhexanide (Akantior) and aflibercept – are

Reata’s Bardoxolone Could Crash In Chronic Kidney Disease Reata Pharmaceuticals, Inc. ’s bardoxolone for chronic kidney disease due to Alport syndrome is expected to get a US Food and Drug Administra

Seres Therapeutics’ SER-109 Seres Therapeutics, Inc. is expected to file for approval of SER-109 in late 2021 or early 2022, paving the way for it to become the first microbiome therapeutic approved